Nordic Nanovector ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.
Nordic Nanovector ASA (8NN) - Net Assets
Latest net assets as of June 2025: €473.50 Million EUR
Based on the latest financial reports, Nordic Nanovector ASA (8NN) has net assets worth €473.50 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€561.00 Million) and total liabilities (€87.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €473.50 Million |
| % of Total Assets | 84.4% |
| Annual Growth Rate | -12.14% |
| 5-Year Change | 88.7% |
| 10-Year Change | N/A |
| Growth Volatility | 119.0 |
Nordic Nanovector ASA - Net Assets Trend (2016–2024)
This chart illustrates how Nordic Nanovector ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nordic Nanovector ASA (2016–2024)
The table below shows the annual net assets of Nordic Nanovector ASA from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €337.14 Million | +23.98% |
| 2023-12-31 | €271.93 Million | +325.93% |
| 2022-12-31 | €63.84 Million | -54.57% |
| 2021-12-31 | €140.52 Million | -21.35% |
| 2020-12-31 | €178.67 Million | -53.95% |
| 2019-12-31 | €388.01 Million | +6.83% |
| 2018-12-31 | €363.19 Million | -46.56% |
| 2017-12-31 | €679.61 Million | -28.41% |
| 2016-12-31 | €949.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nordic Nanovector ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 45056300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €400.20 Million | 118.70% |
| Total Equity | €337.14 Million | 100.00% |
Nordic Nanovector ASA Competitors by Market Cap
The table below lists competitors of Nordic Nanovector ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mccoy Global Inc
PINK:MCCRF
|
$50.85 Million |
|
Rapid Micro Biosystems Inc
NASDAQ:RPID
|
$50.86 Million |
|
Routon Electronic Co Ltd
SHG:600355
|
$50.90 Million |
|
ENTECH SE EO-2
F:0AS
|
$50.91 Million |
|
Cameo Communications Inc
TW:6142
|
$50.85 Million |
|
Ellaktor S.A
AT:ELLAKTOR
|
$50.84 Million |
|
Etoiles Capital Group Co., Ltd. Class A Ordinary Shares
NASDAQ:EFTY
|
$50.84 Million |
|
IMC S.A.
F:IM4
|
$50.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nordic Nanovector ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 271,925,000 to 337,144,000, a change of 65,219,000 (24.0%).
- Net loss of 42,208,000 reduced equity.
- New share issuances of 114,346,000 increased equity.
- Other factors decreased equity by 6,919,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-42.21 Million | -12.52% |
| Share Issuances | €114.35 Million | +33.92% |
| Other Changes | €-6.92 Million | -2.05% |
| Total Change | €- | 23.98% |
Book Value vs Market Value Analysis
This analysis compares Nordic Nanovector ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.03x to 0.35x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €13.72 | €0.42 | x |
| 2018-12-31 | €7.27 | €0.42 | x |
| 2019-12-31 | €5.82 | €0.42 | x |
| 2020-12-31 | €2.23 | €0.42 | x |
| 2021-12-31 | €1.41 | €0.42 | x |
| 2022-12-31 | €0.54 | €0.42 | x |
| 2023-12-31 | €1.13 | €0.42 | x |
| 2024-12-31 | €1.20 | €0.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nordic Nanovector ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-12.52%) is above the historical average (-147.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -24.81% | -75003.18% | 0.00x | 1.10x | €-330.44 Million |
| 2017 | -43.23% | -97289.40% | 0.00x | 1.15x | €-361.78 Million |
| 2018 | -93.00% | 0.00% | 0.00x | 1.30x | €-374.09 Million |
| 2019 | -111.75% | 0.00% | 0.00x | 1.33x | €-472.40 Million |
| 2020 | -233.44% | 0.00% | 0.00x | 1.76x | €-434.94 Million |
| 2021 | -314.06% | 0.00% | 0.00x | 2.11x | €-455.35 Million |
| 2022 | -487.52% | 0.00% | 0.00x | 1.72x | €-317.63 Million |
| 2023 | -9.77% | 0.00% | 0.00x | 1.22x | €-53.75 Million |
| 2024 | -12.52% | 0.00% | 0.00x | 1.23x | €-75.92 Million |
Industry Comparison
This section compares Nordic Nanovector ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nordic Nanovector ASA (8NN) | €473.50 Million | -24.81% | 0.18x | $50.85 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |